Ingalls & Snyder LLC Has $793,000 Stock Position in Sanofi (NASDAQ:SNY)

Ingalls & Snyder LLC lowered its position in shares of Sanofi (NASDAQ:SNY) by 2.4% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 16,445 shares of the company’s stock after selling 400 shares during the quarter. Ingalls & Snyder LLC’s holdings in Sanofi were worth $793,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of SNY. Synergy Asset Management LLC acquired a new stake in shares of Sanofi during the fourth quarter worth $25,000. McClarren Financial Advisors Inc. lifted its holdings in shares of Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after buying an additional 543 shares in the last quarter. Northwest Investment Counselors LLC acquired a new position in Sanofi in the third quarter valued at about $29,000. Concord Wealth Partners raised its stake in Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after purchasing an additional 363 shares in the last quarter. Finally, Fortitude Family Office LLC raised its stake in Sanofi by 708.6% in the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after purchasing an additional 659 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Sanofi has an average rating of “Buy” and an average target price of $60.00.

Sanofi Stock Performance

Sanofi stock opened at $53.99 on Friday. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97. The company has a quick ratio of 0.74, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The business’s 50-day moving average price is $50.18 and its two-hundred day moving average price is $52.42. The stock has a market cap of $137.02 billion, a PE ratio of 21.68, a P/E/G ratio of 0.99 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.58% and a net margin of 12.77%. As a group, analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.